Arcutis Biotherapeutics, Inc.
ARQT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,685 | $224 | $814 | $1,025 |
| - Cash | $71 | $88 | $54 | $96 |
| + Debt | $111 | $206 | $203 | $78 |
| Enterprise Value | $1,724 | $341 | $963 | $1,006 |
| Revenue | $197 | $60 | $4 | $0 |
| % Growth | 229.7% | 1,517.1% | – | – |
| Gross Profit | $177 | $55 | $3 | -$1 |
| % Margin | 90.3% | 91.6% | 79.5% | – |
| EBITDA | -$110 | -$227 | -$295 | -$206 |
| % Margin | -55.8% | -381.6% | -7,991.1% | – |
| Net Income | -$140 | -$262 | -$311 | -$206 |
| % Margin | -71.3% | -439.8% | -8,449.8% | – |
| EPS Diluted | -1.16 | -3.78 | -5.66 | -4.17 |
| % Growth | 69.3% | 33.2% | -35.7% | – |
| Operating Cash Flow | -$112 | -$247 | -$258 | -$175 |
| Capital Expenditures | -$0 | -$0 | -$23 | -$1 |
| Free Cash Flow | -$112 | -$247 | -$281 | -$176 |